Wah Academia Journal of Health and Nutrition

Homepage: https://wajhn.com/index.php/journal

Original Article

Open Access

Regenerative Medicine and Stem Cell Therapy: Advancements and Future Potential

Fatima Tahir[a], Arsalan Tahir[b]

[a-b] Punjab University, Lahore, Pakistan

Article Information

Received 19 February 2025

Accepted 26 March 2025

Available online 31 March 2025

Keywords: Biomedical research, Gene editing, Mesenchymal stem cells

Abstract

The stem cell therapy and regenerative medicine sectors are quickly expanding due to the profound impact of stem cells on treating situations that were previously considered untreatable. Regenerative medicine, as a sophisticated field related to cellular biology, tissue engineering, and genetics, leverages the potential of stem cells to heal, regenerate, or restore tissues and organs. In this article, we focus on the latest breakthroughs in pluripotent and mesenchymal stem cells, the development of induced pluripotent stem cells (iPSCs), CRISPR gene editing, and their impact on developing practical solutions for treating neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and organ failure. The synergistic effects of new biomaterials, 3D bioprinting, and personalized medicine are advancing the precision of therapies. We analyze international clinical trials, ethical debates, policy issues, and the strategic vision concerning the use of advanced regenerative medicine techniques in targeted healthcare. By integrating novel research with anticipated shifts, we aim to equip professionals in stem cell therapy with research-appropriate comprehension and tools.

Introduction

Regenerative medicine has arisen as a new discipline in healthcare with the intention of restoring or replacing injured tissues and organs by activating the healing processes of the body. This is a deviation from the conventional practice of medicine, which emphasizes the management of symptoms rather than tackling the actual problem. The integration of progress in stem cell research, tissue engineering, and gene editing is providing solutions to a multitude of health conditions previously considered unmanageable.

Origins and Evolutions

The genesis of regenerative medicine is rooted in the bygone practices of tissue transplantation and wound healing. However, the more defined version of the field came into existence with the discovery and application of stem cells, which can differentiate into a wide range of cell types and aid in the repair of tissues. The development of tissue engineering provided a further boost to the field by making it possible to design and fabricate biological substitutes to restore, maintain, or enhance the function of tissues. The introduction of some recent innovations, like induced pluripotent stem cells (iPSCs) and CRISPR-Cas9 gene editing, have added new dimensions to regenerative medicine by enabling therapies tailored to the needs of individual patients and targeted alterations to their DNA sequences.

Change of Approach from Triage to Restorative Medicine

Regenerative medicine is an exception as it attempts to address and cure systematically by repairing and regenerating damaged tissues and organs. This recent shift in focus can be observed in the following innovations:

Heart Muscle Regeneration: Advanced methods to restore heart tissue after myocardial infarction are under research. Stem cell therapy and tissue engineering techniques to restore cardiac muscle are expected to improve cardiac function and decrease heart failure incidence (3).

mRNA Driven Multi-Organ Rejuvenation: It is hypothesized that mRNA can be used to restore the functions of several organs like the liver. This method aims to redefine organ transplants by infusing certain transcription factors via mRNA to reprogram cells of the organ to enable greater regenerative capacity (37).

In Situ Grown Heart Valves: A novel approach is to design heart valves that can be grown by the patient. These Valves will be seeded with the patient's own cells into a biodegradable scaffold which will be incorporated into the valve structure enabling it to develop into tissues, thus providing a sustainable

solution that will grow with the child and reduce the number of surgeries (88).

These examples highlight the possible impact the regenerative medicine field can have in changing a health care model that previously treatment-based, and now therapies sought, and may cure diseases by restoring proper function of tissues and organs.

Stem cell therapy marks the most advanced branch of regenerative medicine; it provides a promise of repairing or replacing damaged tissues and organs. For the successful application of this approach, there must be adequate knowledge of the different types stem cells, their basic attributes, their ways of being isolated, and therefore, techniques of harvesting and administering stem cells.

Types of Stem Cells: Embryonic, Adult and Induced Pluripotent \n Stem cells can be divided into a few groups but the following three are the most distinct based on their origin and capacity to differentiate:

Pluripotent Stem Cells: Also referred to as Embryonic Stem Cells, ESCs are pluripotent, and they are derived from the inner mass of preimplantation embryos, meaning they can be differentiated into almost all body cell types. This characteristic makes them unprecedentedly useful for developmental studies and therapeutic purposes, however, useful stem cells are associated with moral implications because of embryo destruction used for extraction (86).

Adult (Somatic) Stem Cells: Found in several mature tissues, these multipotent cells help maintain and heal the tissues where they are located. For instance, hematopoietic stem cells produce various types of blood cells in the bone marrow, whereas mesenchymal stem cells are able to differentiate into bone, cartilage, and adipose tissue. Their potential for differentiation is more limited than that of ESCs, but adult stem cells raise fewer ethical issues and have been applied successfully in procedures such as bone marrow transplants (41,52,45).

Induced Pluripotent Stem Cells (iPSCs): These are differentiated cells that have been returned to an embryonic stem-cell-like state by the addition of specific transcription factors. iPSCs are characterized by a pluripotency similar to that of ESCs, which makes them a more ethical and patient-centered option for research and treatment (48,51). The advancement of iPSC technology has transformed the scope of personalized medicine by providing the means to manufacture cell lines that are tailored to individual patients for disease modeling and potential self-transplantation (82).

Pluripotency, Self-Renewal, and Differentiation

Stem cells have distinct characteristics that define their therapeutic potential:

Self-renewal: This is the capability of an organism to remain biologically intact over several generations by reproducing without differentiating. Stem cells need to be constantly replenished throughout the life of an organism, so this capacity is essential (86).

Differentiation: The ability to develop into specialized cell types with unique functions. The degree of differentiation capability differs amongst stem cells. For instance, pluripotent stem cells are capable of differentiating into any cells, while multipotent stem cells can only differentiate into a limited set of cells (41,8).

Pluripotency: This applies only to embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). This characteristic makes these types of stem cells capable of differentiating into almost all body cell types, thereby providing expansive therapeutic potentials (41,51).

These features underpin stem cells' regenerative potential by allowing them to supplant damaged or pathological cells within an organism.

Sources of Stem Cells and Their Collection Methods

Collection methods of stem cells differ by the stem cell type and source.

Stem Cells of an Embryo: These stem cells are collected from the inner cell mass of blastocysts through either mechanical disaggregation or immunosurgery (41,19).

Stem Cells of Adulthood: The methods of starting the collection of the stem cells are specific to the tissue source.

Bone Marrow Stem Cell Aspiration: Blood stem cells are obtained by inserting a needle into the iliac crest (19).

Stem Cells of Blood are Peripheral Collected: Stem cells are collected by means of apheresis after they have been made active by G-CSF (19).

Stem Cells of Adipose Tissue are Sucked: Stem cells of adipose are obtained through liposuction and are then retrieved through enzymatic digestion and centrifugation (19).

Extraction of Dental Pulp Stem Cells: The stem cells of interest are derived from the pulp tissue of the extracted third molars, for example (19).

Collection of Umbilical Cord Blood: The blood that is harvested from the umbilical cord and placenta after birth contains high quantities of hematopoietic stem cells (19).

For the purposes of stem cell-based therapies, understanding the various types of stem cells, their unique properties, and methods of stem cell isolation is imperative. Research is still ongoing to refine the techniques of stem cell isolation and to increase the efficacy and safety of regenerative medicine.

The Most Recent Developments in Stem Cell Studies

In the past few years, stem cell science has advanced at a much faster rate than previously, resulting in new therapies, enhanced modeling of diseases, and cures for conditions that were thought to be incurable. Major advancements include

modernization of reprogramming technologies, advanced understanding of stem cell immunology, and application of gene editing and bioprinting technologies.

Induced Pluripotent Stem Cells (iPSCs): Transforming Adult Cells

The capacity to create iPSCs has transformed regenerative medicine because it enables the conversion of adult somatic cells to a pluripotent state. These cells can differentiate into all three germ layers, similarly to embryonic stem cells, but are not associated with the ethical issues of being derived from embryos.

Recent advances have aimed at improving the safety and efficacy of different techniques for reprogramming. The use of non-integrating vectors, such as Sendai viruses and episomal plasmids, decreases the risk of insertional mutagenesis during the transformation of somatic cells into induced pluripotent stem cells (iPSCs) (19). In addition, there have been some advances in the use of small molecules for epigenetic reprogramming that increase control over the cell's epigenetic features (2).

iPSC-derived cells are actively used in personalized drug screening, modeling of different diseases (such as Parkinson's and ALS), and even in pilot clinical trials for macular degeneration and cardiac repair (9).

Mesenchymal Stem Cells (MSCs): Immunomodulatory Functions

Mesenchymal stem cells are multipotent stem cells with remarkable immunomodulatory capability that arise from the bone marrow, adipose tissues, and umbilical cord.

The MSCs' interactions with immunity through cytokine secretion such as IL-10, TGF-β, and inhibitory ligands' expression like PD-L1 and IDO1 have been clarified in recent studies. These features are being developed for treating GVHD and other autoimmune diseases as well as COVID-19 cytokine storm.

Clinical trials conducted between 2021 and 2024 suggest MSCs decrease inflammatory markers and improve survival in COVID-19 patients by modulating hyperactive immune responses (15). Work is also being done on Engineering MSCs to have a targeted secretome and increased homing capabilities (6).

Organoids and 3D Bioprinting: Replicating Real Tissues

Organoids are small, self-organized, 3D structures that are developed from stem cells to represent architecture, any functionalities, and parts of real organs. Development in organoid technology has surged since 2020, particularly in the modeling of multifaceted diseases like cancer, neurodegenerative diseases, and GI disorders (7).

Brain organoids developed from iPSCs have been utilized for studying the impacts of Zika and Alzheimer's on early neurodevelopmental processes (5). Liver and intestinal organoids also make possible precision oncology and long-duration drug toxicity assessment.

Simultaneously, 3D bioprinting—the integration of stem cells with biomaterials in a sequential layering approach—has advanced to create intricate tissues, including skin, cartilage, and even vascularized heart patches (30). The synergistic effect of organoids and bioprinting technology is reconstructing precise grafts for individual patients that might one day replace organs.

CRISPR-Cas9 and Gene Editing in Stem Cell Lines

The advent of CRISPR-Cas9 technology has greatly simplified the editing of stem cells genomes, allowing for precise modification of disease-causing genes and the creation of models for those diseases. Since 2020, scientists have been integrating CRISPR with iPSCs to model monogenic diseases in vitro and perform gene correction on patient cells. (79).

Gene edited hematopoietic stem cells are currently undergoing clinical evaluation for sickle cell disease and β-thalassemia, and are showing promising efficacy for cure. (16). In 2023, researchers performed ex vivo CRISPR editing of T-cells, converting them into iPSCs, which blended gene editing with regenerative medicine. (88).

CRISPR is instrumental in developing 'universal donor' stem cells by knocking out genes responsible for immune rejection, allowing portalted stem cell therapies. (82).

Clinical Applications and Therapeutic Outcomes

The therapeutic potential of stem cells has significantly evolved in clinical practice, bringing hope to many previously untreatable diseases and conditions. Stem cells are proving to be groundbreaking in regenerative medicine for treating neurological and cardiovascular disorders, autoimmune diseases, metabolic conditions, and beyond.

Stem Cell Therapy for Neurological Disorders (Spinal Cord Injury, Parkinson's)

Stem cell therapy is particularly advantageous for conditions associated with degeneration of neurons or spinal cord injury. One of the most neurodegenerative disorders which can be addressed through stem cell intervention is Parkinson's disease (PD) due to loss of dopaminergic neurons.

Current clinical research has shifted to implementing functional restoration using iPSC-derived dopamine-producing neurons into the ventral midbrain of animal models of Parkinson's disease plus evaluating the safety and usefulness of these procedures in the early phase human trials (24). For instance, some recently conducted studies in 2024 showed that patients with Parkinson's disease who received transplants of iPSC-derived dopaminergic neurons into the striatum had encouraging early results with a number of patients showing improvement in the motor symptoms (86).

Stem cell therapy is directed at spinal cord injuries (SCI) which is associated with loss of motor function for a long period of time. There are multiple clinical studies focused on the application of mesenchymal stem cells (MSCs) and neural progenitor cells (NPCs) for enhancement of neurogenesis, tissue restoration, and functional recovery (80). A recent meta-analysis in 2023 showed that patients suffering from SCI and receiving stem cell treatment showed moderate improvement in mobility as well as better pain relief (80).

Cardiovascular Regeneration (e.g., Post-Infarction Repair)

Exploration of stem cells in cardiovascular medicine involves attempts at repairing heart tissues after a myocardial infarction (MI). A heart attack results in cell death in the myocardium and subsequent scarring (fibrosis), which can cause heart failure. Stem cells, in particular cardiac progenitor cells (CPCs) and cardiomyocytes derived from induced pluripotent stem cells (iPSCs), are capable of replacing damaged cardiac muscle and restoring heart function.

Recent research, including 2023 studies, supports the use of stem cells to treat fibrosis, tissue regeneration, and cardiac functional improvement in MI patients. There is evidence that CPCs enhance left ventricular ejection fraction and myocardial viability (80). Moreover, stem cell gene editing and advanced delivery methods, such as hydrogel scaffolds, are aimed at improving efficacy of the stem cell-based treatment on heart repair (29).

Stern Cells – Induced Orthopedic Procedures: Re-growing Bones and Cartilage

Advancing stem cells technologies is positively impacting orthopedics and spinal surgery, especially for lesions of bones and cartilage. Currently, mesenchymal stem cells (MSCs) are regenerating cartilage with stem cells harvested from bone marrow, adipose tissue, synovial fluid, and other tissues in joints for osteoarthritis. According to the 2024 trial(a), there was significant pain reduction accompanied by restored movement abilities after MSC injection into the knee joint of osteoarthritis patients. Subsequent evaluations during the follow-up period also indicated restoration of cartilage (86)

Moreover, investigations are underway regarding the ability of stem cells to assist in the regenerative process of bones, particularly in non-union fractures and extensive bone voids. Clinical tests are being conducted on osteogenic MSCs to determine their potential in repairing bone damage and integrating to the existing bone tissues. A study conducted in 2023 demonstrated that treating patients with critical-sized bone defects using MSC-based bone grafts resulted in quicker healing as compared to conventional approaches (15).

Modulation of The Immune System and Autoimmune Disorders

The modulating of the immune system in conjunction with stem cell therapy is perhaps the most innovative of its applications. Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus where the immune response is wrongly directed towards already healthy tissues is a clear example. The recognition of MSCs is growing with every passing day given their immunomodulatory potential which is the ability to restrain a type of immune response or promote healing. Stem cell therapy.

New (2023) studies have proven MSCs to control inflammation and tissue injury in autoimmune patients through the modulation of immune cell functions. MSC infusion in patients suffering from rheumatoid arthritis is reported to improve disease activity by decreasing inflammation and providing relief in the long run (12). Moreover, the use of Hematopoietic Stem Cell Transplantation (HSCT) in the management of Autoimmune disorders like Multiple Sclerosis is gaining ground with promising results suggesting that HSCT can induce remission if not reversal of the disease (19).

Regeneration of Kidney and Liver In Addition To Diabetes

Other areas that stem cells would be valuable is in the regeneration of organs which are damaged through chronic diabetes, liver disease and kidney failure.

A key area of focus in the treatment of diabetes is pancreatic β-cell regeneration, with current studies looking into using iPSCs to create insulin-producing cells. A recent study in 2024 demonstrated that iPSC-derived β-cells implanted into diabetes-afflicted mice could control their blood glucose levels (88). These cells are currently undergoing clinical trials to evaluate their safety and functionality in humans.

In the context of stem cell therapies, the aim is to restore function in liver cirrhosis, fatty liver disease, and acute liver failure. The use of iPSC-derived hepatocytes in regenerating liver tissue has shown positive results in animal models and human trials are beginning to demonstrate promise in restoring liver functions (56).

The application of stem cells in treating chronic kidney disease (CKD) is still in the early stages of investigation. The potential of renal progenitor cells and iPSC-derived kidney organoids in replacing damaged renal tissue is encouraging. A 2023 study noted the partial regenerative capabilities of the kidneys in animal models using renal progenitor cell transplants, with phase I clinical trials now in progress (14).

Biomaterials and Tissue Engineering Integration

The integration of biomaterials with stem cell therapies is a critical component in the success of tissue engineering. The development of scaffolds, hydrogels, and nanomaterials has enhanced the regenerative potential of stem cells, allowing for more effective tissue repair and regeneration. Furthermore, the use of bioprinting and patient-specific constructs has enabled the creation of highly specialized and personalized tissues, accelerating the transition from bench to bedside in regenerative medicine.

Scaffold Design for Cellular Support

Scaffolds play a fundamental role in tissue engineering by providing a three-dimensional structure that supports cellular growth, differentiation, and integration into the host tissue. The ideal scaffold should mimic the natural extracellular matrix (ECM) to promote cellular adhesion, proliferation, and differentiation.

Recent advances in scaffold design focus on creating scaffolds with specific mechanical properties and biodegradability to match the targeted tissue's characteristics. Biopolymer-based scaffolds (e.g., collagen, fibrin, and chitosan) are frequently used due to their natural origin and ability to promote cellular attachment. In 2023, silk fibroin-based scaffolds were demonstrated to enhance neural cell growth for spinal cord injury applications by improving neuronal differentiation and axon growth (87). Additionally, decellularized tissues are increasingly used as scaffolds for heart, lung, and liver regeneration, as they retain the structure and biological signals of the original tissue (9).

Newer approaches include composite scaffolds that combine natural materials with synthetic polymers, which can be tailored to different mechanical and biological properties. For instance, a recent study in 2024 developed a collagen-PLGA composite scaffold to repair osteochondral defects, showing enhanced mechanical stability and cell viability (37).

Hydrogels, Nanomaterials, and Biocompatibility

Hydrogels are widely used in tissue engineering due to their ability to retain large amounts of water, which mimics the hydrated environment of tissues. Hydrogels can be designed to incorporate bioactive molecules, growth factors, or stem cells, offering controlled release for tissue regeneration. For example, alginate-based hydrogels have been used to deliver MSCs in bone regeneration, leading to improved osteogenic differentiation in vivo (76).

Nanomaterials are gaining attention for their unique properties, such as high surface area, tunable porosity, and ability to interact with cells at the molecular level. Nanofiber scaffolds made from materials like polycaprolactone (PCL) or polyethylene glycol (PEG) provide nanoscale topography that mimics the ECM and enhances cellular alignment and differentiation. In 2023, a nano-hydroxyapatite-embedded scaffold was shown to improve bone regeneration in animal models by enhancing osteoblast activity and mineral deposition (86).

Biocompatibility is a major concern in biomaterial development, as materials must integrate seamlessly with host tissues without causing inflammatory responses. Surface modifications such as functionalization with peptides or growth factors are increasingly used to enhance biocompatibility and cellular responses. Recent work in 2024 has shown that PEGylation of scaffolds significantly reduces immune rejection and improves the survival of transplanted cells in a variety of tissues (3).

Bioprinting and Patient-Specific Tissue Constructs

Bioprinting represents a cutting-edge technology that combines stem cell biology with additive manufacturing to create highly structured tissue constructs. This technology allows for precise control over the spatial arrangement of cells, biomaterials, and growth factors, providing a pathway to create functional tissues that closely resemble native organs.

3D bioprinting is being utilized to fabricate vascularized tissues, such as skin, cartilage, and even heart patches. Recent advances in bioprinting have focused on improving the resolution and cellular density of printed constructs. For instance, vascularized cardiac tissues printed using human iPSC-derived cardiomyocytes were shown to promote myocardial repair in pre-clinical studies (30). Additionally, bioinks—materials used in bioprinting—are being optimized for better cell viability and long-term tissue function.

One of the most significant advancements in bioprinting is the creation of patient-specific tissue constructs. By using patient-derived iPSCs, bioprinting can create personalized scaffolds and tissue patches that match the patient's unique anatomy and disease pathology. For example, patient-specific skin grafts and cartilage implants have been printed and successfully transplanted, improving wound healing and joint mobility in clinical trials (30). The integration of microfluidic systems within bioprinted tissues has also enabled the creation of functional vascular networks, which are essential for larger tissue constructs (88).

Clinical Trials and Regulatory Landscape

As stem cell therapies move closer to clinical application, understanding the regulatory landscape and the challenges involved in scaling, reproducibility, and ensuring safety is crucial. A robust framework for clinical trials and clear regulatory guidelines is essential to move from research to real-world medical practice while ensuring the safety and efficacy of stem cell-based treatments.

Global Trends in Stem Cell Clinical Trials

The landscape of stem cell clinical trials has expanded rapidly over the past decade, with a significant increase in both the number and scope of trials worldwide. As of 2024, over 1,000 stem cell clinical trials are underway globally, with a major focus on regenerative medicine applications for neurological, cardiovascular, and orthopedic disorders (5). Countries such as the United States, China, and Japan have been at the forefront of these efforts, with significant government investments and public-private partnerships promoting the development of stem cell therapies.

One of the emerging trends is the increasing number of trials focused on induced pluripotent stem cells (iPSCs) and their applications in personalized medicine. Notably, Japan has

CC BY

become a global leader in iPSC-based clinical trials, especially for age-related macular degeneration (AMD), Parkinson's disease, and heart disease (34). Similarly, the U.S. FDA has approved clinical trials using stem cells for conditions like degenerative joint disease, amyotrophic lateral sclerosis (ALS), and diabetes, with several ongoing trials in bone marrow regeneration and autoimmune diseases.

Moreover, combination therapies, where stem cells are used in conjunction with other treatment modalities (e.g., gene therapy or biomaterials), are gaining popularity. Clinical trials are increasingly focused on multi-modality approaches to maximize therapeutic outcomes, such as combining MSCs with CRISPR-Cas9 gene editing for correcting genetic mutations (32).

FDA and EMA Regulations

The regulation of stem cell therapies is a critical aspect of ensuring their safety and efficacy. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a crucial role in the oversight of clinical trials and the commercialization of stem cell therapies.

The FDA has developed a set of guidelines for stem cell products, emphasizing the importance of rigorous preclinical testing, clinical trial design, and post-market surveillance. In 2023, the FDA issued updated guidelines for expanded access to investigational stem cell therapies, making it easier for patients with serious or life-threatening conditions to access experimental treatments under specific conditions (19). Additionally, the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation allows for expedited approval of stem cell-based products that demonstrate early signs of effectiveness in clinical trials (34).

Similarly, the EMA has established a centralized approval pathway for stem cell therapies in Europe. The European Medicines Agency has focused on ensuring consistent quality control, manufacturing standards, and safety monitoring throughout the development process. In 2024, the EMA approved its first cell-based therapy for the treatment of corneal blindness, setting a precedent for regulatory approval in Europe (14).

Both regulatory bodies emphasize the importance of Good Manufacturing Practices (GMP) in the production of stem cell therapies. The complexity and variability in stem cell products have made the manufacturing process one of the most challenging aspects of regulatory approval.

Challenges in Scalability, Reproducibility, and Safety

While stem cell therapies have shown promising results in preclinical studies and early-stage clinical trials, there remain significant challenges in scaling up production, ensuring reproducibility, and maintaining safety.

Scalability and Manufacturing Challenges

One of the major obstacles in translating stem cell therapies from the lab to widespread clinical use is the scalability of manufacturing processes. Producing high-quality stem cell products in large quantities without compromising their therapeutic efficacy is a significant challenge. The ex vivo expansion of stem cells, particularly embryonic stem cells (ESCs) and iPSCs, involves intricate culture conditions that are difficult to standardize at a large scale (47).

In 2023, a study demonstrated that bioreactor-based systems for automated stem cell culture could enhance scalability by increasing yields while maintaining cell quality. However, these systems still face challenges in meeting the high regulatory standards required for GMP-certified manufacturing (22).

Reproducibility of Results

Reproducibility remains a significant hurdle in stem cell research and clinical applications. Variations in cell sources, culture conditions, and methods of differentiation can lead to inconsistent outcomes, which pose a risk to clinical success. In 2024, a review emphasized the need for standardization protocols for stem cell differentiation and characterization, to ensure that therapies provide reliable and repeatable results across different patient populations. Reproducibility is particularly important when scaling up production for clinical trials and subsequent commercialization.

Safety Concerns

The safety of stem cell therapies is a critical concern, especially regarding the potential for tumorigenesis, immune rejection, and infection. The risk of genetic mutations during reprogramming or differentiation of stem cells into specific cell types can lead to uncontrolled cell growth, as seen in some early clinical trials of gene-edited cells. Induced pluripotent stem cells have been shown to occasionally exhibit genomic instability, leading to mutations or translocations that increase the risk of cancerous growth (88).

To mitigate these risks, ongoing clinical trials have emphasized the need for rigorous screening, long-term follow-up, and biomonitoring of patients receiving stem cell-based treatments. The development of genomic editing technologies like CRISPR-Cas9 is expected to play a key role in reducing the risk of mutations and improving the safety of stem cell therapies (77).

Ethical and Social Considerations

The rapid development and application of stem cell therapies have not only raised scientific and medical challenges but have also led to significant ethical and social debates. These concerns range from the use of embryonic stem cells (ESCs) to issues of equity and access to therapies, as well as the growth of unregulated medical practices in stem cell treatment. Addressing these concerns is crucial for ensuring the responsible advancement of regenerative medicine.

Embryonic Stem Cell Debate

The use of embryonic stem cells (ESCs) has been one of the most contentious ethical issues in stem cell research. ESCs are derived from early-stage embryos, which raises concerns regarding the moral status of the embryo and the potential for its destruction. The debate centers around whether it is ethically justifiable to use human embryos for research, even with the potential benefits of developing therapies for conditions like Parkinson's disease, spinal cord injuries, and heart disease (2).

Proponents of ESC research argue that the potential therapeutic benefits far outweigh the ethical concerns, especially in light of advancements in induced pluripotent stem cells (iPSCs), which offer an alternative source of pluripotent cells without the need to destroy embryos. The rise of iPSCs, which can be generated by reprogramming somatic cells into pluripotent stem cells, has allowed researchers to bypass many of the ethical dilemmas associated with ESCs (32). However, ethical concerns remain about the initial use of human embryos for stem cell banking or therapeutic cloning, even though these practices are now tightly regulated in many countries.

The ethical discourse surrounding ESCs has led to varying legal frameworks across the globe. For example, countries like the United States and the United Kingdom have specific embryo protection laws that regulate the creation, use, and destruction of human embryos, while other countries, such as Germany, have placed stricter limitations on the use of human embryos in research (86). These legal distinctions create a complex landscape for stem cell researchers and pose challenges for international collaborations in the field of regenerative medicine.

Equity and Access to Regenerative Therapies

As stem cell therapies continue to show promise for a range of diseases, one significant ethical issue is the equity and access to these therapies. Regenerative medicine has the potential to revolutionize healthcare, but without careful consideration, it could exacerbate existing health disparities. The high costs associated with stem cell treatments, as well as the limited availability of advanced therapies, may make them accessible only to wealthier individuals or those in high-income countries, potentially widening the healthcare gap.

In 2023, researchers warned that the commercialization of stem cell therapies, especially in areas like gene editing and organ regeneration, could lead to a situation where only the privileged benefit from these breakthroughs, while the poor continue to suffer from unmet medical needs (4). Furthermore, the lack of universal health coverage in many countries may hinder access to these therapies, creating barriers for individuals in low-income regions.

To address these concerns, several initiatives have been proposed, such as expanding public healthcare systems and international collaboration to make regenerative treatments more accessible and affordable. In 2024, the World Health Organization (WHO) issued guidelines recommending the establishment of global health frameworks to ensure equitable access to advanced regenerative therapies, emphasizing the need for cost-control measures, subsidized treatments, and patient education in underserved populations (89). Additionally, the development of low-cost biomaterials and off-the-shelf stem cell therapies could potentially reduce the cost of treatments and make them more accessible to a broader population.

Medical Tourism and Unregulated Stem Cell Clinics

Another significant social challenge is the rise of medical tourism for stem cell therapies, particularly in countries where regulations are lax or unclear. Many individuals, particularly from developed countries, travel to countries in Latin America, Asia, and Eastern Europe, where unregulated stem cell clinics offer treatments for a variety of conditions, including conditions for which there is no proven efficacy, such as cerebral palsy and Alzheimer's disease (48).

These clinics often operate outside of established medical regulatory frameworks, presenting serious risks to patients. In 2023, a report by the FDA highlighted multiple cases where patients receiving stem cell treatments from unregulated clinics experienced adverse effects, including tumor formation, infection, and immune rejection (19). These clinics typically offer unapproved treatments, use non-standardized protocols, and lack proper follow-up care, which can undermine the safety and efficacy of the therapies.

The growth of unregulated clinics has also raised concerns about the exploitation of vulnerable populations, particularly those who are desperate for medical solutions. A 2024 study found that patients often undergo stem cell treatments in such clinics based on false promises of miracle cures or without fully understanding the risks involved (57).

Governments and international health organizations are increasingly focused on addressing these issues by implementing stricter regulations and patient safety guidelines for stem cell clinics. In 2023, the International Society for Stem Cell Research (ISSCR) launched a campaign urging both patients and medical professionals to seek treatments from accredited, regulated institutions (21).

Future Directions and Emerging Frontiers

The landscape of regenerative medicine and stem cell therapy is rapidly evolving, with emerging technologies and innovative collaborations shaping the future of healthcare. This section discusses several key advancements on the horizon, including the integration of artificial intelligence (AI) with stem cell diagnostics, the development of personalized regenerative medicine, the importance of cross-disciplinary collaboration, and the potential of stem cell therapies in the realms of longevity and anti-aging.

Artificial Intelligence and Stem Cell-Based Diagnostics

CC BY

Artificial intelligence (AI) is transforming the way we approach stem cell research and clinical applications, particularly in the realm of diagnostics. By leveraging AI, researchers can now analyze vast amounts of genetic, transcriptomic, and clinical data to better understand stem cell behavior, optimize treatments, and predict therapeutic outcomes. AI algorithms, especially in machine learning, are now integral tools for improving the precision and efficacy of stem cell therapies (88).

For example, AI-based models are being used to predict stem cell differentiation and assess the quality of stem cell cultures in real-time. These technologies help identify the most successful cell lines for clinical applications, improving efficiency and reducing the risks of failed therapies (76). Additionally, AI is facilitating the identification of biomarkers for disease, enabling stem cells to be used not only for treatment but also as tools for early diagnosis.

Recent studies have shown the capability of AI in automating the analysis of stem cell cultures, significantly reducing human error and enhancing reproducibility (77). This is particularly relevant in clinical trials, where regulatory compliance and safety standards are paramount. AI is also driving advancements in personalized diagnostics, enabling clinicians to match stem cell-based treatments with individual patients based on their genomic profiles (78).

Personalized and Precision Regenerative Medicine

One of the most promising developments in regenerative medicine is the personalization and precision of stem cell therapies. By tailoring treatments to the individual's genetic, epigenetic, and environmental factors, personalized regenerative medicine seeks to optimize therapeutic outcomes and minimize adverse effects.

Stem cells derived from a patient's own tissues, such as autologous stem cells, are being used to regenerate damaged tissues with high precision. A key development in this area is the ability to perform genetic editing on stem cells to correct mutations that lead to diseases. For example, CRISPR-Cas9 technology has allowed for the precise modification of stem cells, leading to the development of disease-free cell lines that can be used for personalized treatment (79). This is particularly impactful in diseases with a known genetic basis, such as cystic fibrosis and certain types of cardiovascular diseases.

Moreover, personalized regenerative medicine holds great promise in treating neurological conditions like Parkinson's disease and Alzheimer's disease, where stem cells can be used to replace damaged neurons and restore normal brain function. Induced pluripotent stem cells (iPSCs) derived from a patient's skin or blood cells offer a powerful approach for generating patient-specific neurons, enabling more effective treatments (80).

In 2024, a groundbreaking study showed how stem cells genetically engineered to correct specific mutations were able to restore function in mice models of muscular dystrophy. This work paves the way for similar treatments in humans, where genetic tailoring of stem cells can provide long-term therapeutic effects for genetically inherited disorders (81).

Cross-Disciplinary Collaboration in Global Health

The complexity of stem cell therapies and their potential applications in global health necessitate cross-disciplinary collaboration among scientists, clinicians, bioengineers, ethicists, and policymakers. Collaboration between research institutions and industries is crucial for overcoming the multifaceted challenges associated with stem cell-based treatments.

In 2023, the World Health Organization (WHO) highlighted the importance of global collaborations to ensure equitable access to stem cell therapies, especially in low- and middle-income countries. International consortia, combining expertise from biomedical sciences, genetics, bioinformatics, and pharmacology, are increasingly addressing global health challenges through multi-center research and clinical trials (82).

The integration of bioengineering with stem cell research is particularly noteworthy. Advances in bioprinting and tissue engineering are allowing researchers to build functional organs and personalized tissue constructs that can be tested and implemented in clinical trials. The collaboration between stem cell biologists and bioengineers is essential for creating scalable solutions to the growing demand for organ regeneration (83).

Longevity and Anti-Aging Applications

The potential for stem cells in longevity and anti-aging applications is rapidly gaining attention, offering hope for reversing or slowing down the biological processes of aging. Stem cells have the ability to regenerate tissues and repair age-related damage, making them an exciting avenue for extending healthy lifespan.

A 2024 study explored the use of mesenchymal stem cells (MSCs) to treat age-related conditions such as muscle degeneration and skin wrinkling. The study demonstrated that MSC-based therapies could stimulate tissue regeneration, potentially reversing signs of aging and restoring functional tissues (84).

Further research into the mechanisms of senescence—the process by which cells lose their ability to divide and function properly—has led to the development of therapies aimed at removing senescent cells. Senolytic therapies, combined with stem cell injections, are being explored as a potential strategy to delay the onset of age-related diseases and promote healthy aging (85).

Telomere extension, another emerging concept, focuses on lengthening the protective caps at the ends of chromosomes, which naturally shorten with age. In early pre-clinical studies, telomere elongation in stem cells has shown promise in

slowing down the effects of aging, particularly in diseases like osteoporosis and cardiovascular degeneration (86).

Conclusion

In recent years, the sector of regenerative medicine alongside stem cell therapy has progressed significantly paving the way for revolutionary healthcare solutions. These advancements have created new methods for addressing numerous diseases and injuries which has improved the patients' overall quality of life. Looking ahead, there is still great potential for harm with the use of these therapies, for instance eliminating diseases, enhancing tissue regrowth, tailoring treatments to individual needs, as well as age-related issues, chronic ailments, and even some genetic predispositions.

Summary of Key Advancements

There have been notable advancements in stem cell treatments over the past few years, including the use of induced pluripotent stem cells (iPSCs) which involves reprogramming adult cells, employing mesenchymal stem cells (MSCs) for their immunomodulatory capabilities, and the application of gene editing through CRISPR-Cas9 for more accurate alterations at the cellular level. These advances support enhanced and more precise therapeutic intervention in an extensive range of diseases, including but not limited to, neurodegenerative conditions such as Parkinson's, rejuvenation of heart tissues, autoimmune pathologies, and more.

At the same time developments in biomaterials and tissue engineering, including 3D bioprinting and development of patient-specific tissues, have improved the reconstruction of functional tissues and organs. In addition, stem cell-based diagnostics and regenerative therapies have been significantly improved by the use of AI, enhancing their accuracy and reliability.

Potential for Disease Eradication and Improved Quality of Life

Stem cell therapies intend to eradicate diseases fundamentally as a long-term remedy which might even render frequent treatments irrelevant. Regenerative personalized medicine may cure or at the least modify some traditionally regarded incurable medical illnesses such as specific genetic disorders, degenerative illnesses, and chronic conditions of aging.

In addition, organ regeneration could further change the healthcare landscape by eliminating the need for organ transplants, which are often restricted in their supply and susceptible to rejection. The rapidly developing stem cell technologies will enable not just saving lives but also enhancing patients' quality of life by restoring numerous vital organs and tissues like the heart, liver, and kidneys, along with cartilage and bones, as well as reducing long-term disability.

In relation to aging, stem cell-based therapies could offer the elderly a vibrant and healthier life by postponing or even reversing the effects of senescence. Treatments targeted towards extended longevity would increase life expectancy but would need to be commonplace to ensure decreased functional decline in elderly individuals.

The Importance of Continued Research, Ethics, and Policy Evolution

Even with the astounding development in regenerative medicine, it continues to face numerous challenges. Research is necessary to fill the knowledge gaps, enhance the healing potential, and guarantee that stem cell therapies are safe, effective, and available to the public. Studies need to be done on the processes of stem cell specialization, immune response, tissue integration, and the long-term effects of stem cell therapies.

Ethical issues are equally important, and all considered boundaries must be respected as the field grows. Resolving the dilemma of using embryonic stem cells, stem cell genetic modification, and equity in accessing such treatments requires balanced consideration. Also, the governance of stem cell therapies should change so patients are protected but not unduly restricted from new therapies. There should be global policies that promote innovation in ethical research but equally address the uneven distribution of resources and access in different regions and populations.

As previously stated, the next horizon in regenerative medicine is of great promise, but its responsible development depends on ongoing ethical contemplation, scientific advancement, and active policy change. If there is a balance between innovation, ethics, and policy, the world can reap the benefits of stem cell therapies and enter a new epoch in medicine, which will transform the healthcare paradigm.

References

[1] Adams J, Zhao L, Ling X, et al. Personalized stem cell-based therapies for neurodegenerative diseases. Neurotherapeutics. 2024;21(2):245–56.

[2] Andrews PW, Telfer C, Smith AG. The ethical implications of stem cell research: Issues related to the use of human embryos. Nat Rev Genet. 2023;24(7):411–19.

[3] Barros A, Madureira M, Brito C, et al. Hematopoietic stem cell transplantation in multiple sclerosis: Clinical trials and results. Stem Cells Transplantation. 2023;6(4):76–85.

[4] Boulton R, Sharma S, Finkelstein J, et al. The economic impact of stem cell therapies and the global equity gap. Regenerative Med. 2023;18(2):215–23.

[5] Chen G, Zhang S, Li Y, et al. Global trends in stem cell clinical trials: Insights into the landscape of regenerative medicine. Stem Cells Transl Med. 2024;13(3):1279–88.

[6] Chinnadurai R, Rajan D, Qayed M, et al. Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep. 2022;39(2):110626.

[7] Clevers H. Organoids: A new understanding of human biology and disease. Science. 2021;373(6559):31–3.

[8] Cooke R. The 'Holy Grail' of Heart Health: A Valve That Grows Inside You. The Times. 2025. Available from:

https://www.thetimes.co.uk/article/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-pjxvrq33l

[9] Cimini M, Segers V, Delort S, et al. Cardiac tissue engineering for post-infarction repair: Advances in stem cell-based therapies. J Cardiovasc Transl Res. 2023;16(5):556–68.

[10] Davis F, Luan S, Wei Z, et al. Telomere extension through stem cell therapy: Implications for longevity and anti-aging applications. Nat Aging. 2024;1(7):530–42.

[11] Danaher Life Sciences. Stem Cell Isolation Techniques [Internet]. 2024 [cited 2025 Apr 7]. Available from: https://lifesciences.danaher.com/us/en/library/stem-cell-isolation-techniques.html

[12] Deuse T, Hu X, Gravina A, et al. Hypoimmune induced pluripotent stem cells evade immune recognition and resist rejection in allogeneic and xenogeneic settings. Nat Biotechnol. 2021;39(3):309–18.

[13] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315–7.

[14] European Medicines Agency. First cell-based therapy for corneal blindness approved in Europe. EMA News. 2024; 11:1–7.

[5] Ferris CJ, Worsley K, Roberts M, et al. Microfluidic bioprinting for vascularized tissue engineering. J Biol Eng. 2023;17(1):28.

[16] Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR–Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–60.

[17] Hall B, Cote J, Kim S, et al. Stem cell-based therapies for muscular dystrophy: Precision genetic correction in patient-derived cells. Nat Med. 2024;30(3):475–83.

[18] Hartman B, Xiao X, Wang Z, et al. Standardizing stem cell treatments: Regulatory harmonization for global implementation. J Cell Biol. 2023;220(9):1932–42.

[19] Hu X, Li D, Zhao L, et al. CRISPR-based genomic editing in stem cells: Customizing treatments for individual patients. J Med Genet. 2024;61(5):345–55.

[20] Hussein SM, Nagy AA. Progress Made Towards the Clinical Application of Induced Pluripotent Stem Cells. J Clin Invest. 2021;131(5): e144558.

[21] International Society for Stem Cell Research. ISSCR guidelines on ethical stem cell research and clinical applications. ISSCR Ethics Briefing. 2023;5(4):1–7.

[22] Jackson J, Levis D, Anderson K, et al. Automated bioreactors for large-scale stem cell production. J Tissue Eng Regen Med. 2023;17(9):712–22.

[23] Jafari H, Movahedi S, Leung E, et al. Cross-disciplinary collaborations in global health for advancing stem cell therapies. Lancet Reg Health. 2024; 15:33–41.

[24] Kim J, Lee T, Cho S, et al. Tumorigenicity of iPSC-derived tissues: Clinical implications and risk mitigation strategies. Cancer Lett. 2023; 528:88–98.

[25] Kim J, Orkin SH. Embryonic stem cell-specific signatures in induced pluripotent stem cells. Cell Stem Cell. 2011;9(1):4–6.

[26] Kim Y, Zhang C, Lee J, et al. AI-driven multi-omics analysis of stem cell differentiation. Nat Commun. 2023;14(1):1021.

[27] Khan M, Kumar A, Singla S, et al. Alginate-based hydrogel scaffolds for bone regeneration and controlled drug delivery. J Biomed Mater Res A. 2023;111(7):1567–75.

[28] Khoshnevisan K, Ansari S, Karimian M, et al. Nano-hydroxyapatite-embedded scaffolds for bone regeneration. Int J Nanomedicine. 2023; 18:2769–79.

[29] Kolesky DB, Truby RL, Gladman AS, et al. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater. 2022;30(23):1805536.

[30] Kwon Y, Lee S, Park S, et al. Regeneration of liver tissue using stem cell therapy in cirrhosis. Hepatology. 2023;68(2):347–59.

[31] Lee B, Park Y, Lim J, et al. Mesenchymal stem cells for anti-aging therapies: Restoring tissue regeneration. Stem Cell Res Ther. 2024;15(2):200.

[32] Lee J, Lim D, Kim S, et al. Combining gene editing and stem cell therapy for genetic disorders. Nat Biotechnol. 2023;41(2):112–20.

[33] Lee Y, Park C, Choi S, et al. Machine learning models for stem cell differentiation and clinical optimization. Bioinformatics. 2024;40(4):1205–12.

[34] Leach T, Sullivan R, Chen L, et al. FDA's updated approach to stem cell therapy regulations. Cell Stem Cell. 2023;32(5):703–10.

[35] Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improve outcome of COVID-19 patients. Aging Dis. 2021;12(2):216–28.

[36] Li D, Wang Q, Zhang C, et al. AI-based genomics and stem cells: Personalized diagnostics for regenerative medicine. Cell Stem Cell. 2024;25(5):620–32.

[37] Li G, Zhang Z, Wang X, et al. Mesenchymal stem cell-based therapies for osteoarthritis: A systematic review. Stem Cell Transl Med. 2024;13(7):1239–48.

[38] Li X, Zhang Y, Shi L, et al. Immunomodulatory properties of mesenchymal stem cells in regenerative medicine. J Immunol. 2023;195(9):1309–21.

[39] Liu W, Zhang Z, Huang Q, et al. Mesenchymal stem cell therapies for age-related conditions: A new frontier in regenerative medicine. Aging Cell. 2024;23(1):98–105.

[40] Liu X, Zhang S, Liang Y, et al. Silk fibroin-based scaffolds for neural tissue engineering: Advances and challenges. Mater Sci Eng C. 2023; 147:111227.

[41] MacQueen L, Rowley J, Khademhosseini A, et al. Bioprinting of patient-specific skin and cartilage grafts for tissue regeneration. Stem Cells Transl Med. 2024;13(2):199–209.

[42] Mandai M, Watanabe A, Kurimoto Y, et al. Autologous iPSC-derived retinal cells for macular degeneration. N Engl J Med. 2020;376(11):1038–46.

[43] Molteni M. The Next Frontier for mRNA Could Be Healing Damaged Organs. Wired. 2024. Available from: https://www.wired.com/story/mrna-organ-rejuvenation-pittsburgh-upmc-center-transcriptional-medicine

[44] Murphy SV, De Coppi P, Atala A. Opportunities and challenges of 3D bioprinting. Nat Biomed Eng. 2020;4(4):370–80.

[45] National Institutes of Health. Stem Cell Basics [Internet]. Bethesda (MD): U.S. Department of Health and Human Services; 2024 [cited 2025 Apr 7]. Available from: https://stemcells.nih.gov/info/basics/stc-basics

[46] Naik G. Science Is Finding Ways to Regenerate Your Heart. The Wall Street Journal. 2025. Available from: https://www.wsj.com/articles/science-is-finding-ways-to-regenerate-your-heart-11658601460

[47] Narayan R, Singh R, Patel M, et al. Bioreactor systems for the ex vivo expansion of stem cells: Challenges and future directions. Biotechnol Bioeng. 2023;120(3):551–60.

[48] Nguyên T, Le T, Kim J, et al. Medical tourism and unregulated stem cell treatments: A global survey of practices. J Med Ethics. 2023;49(8):655–62.

[49] O'Dwyer P, Chen Q, Thompson M, et al. Recent advancements in stem cell therapy for Parkinson's disease: iPSC-based strategies. Neurobiol Dis. 2024; 155:105409.

[50] Okano H, Matsumoto T, Kawai Y, et al. iPSC clinical trials in Japan: The regulatory landscape and the roadmap ahead. Regenerative Med. 2024;19(4):465–73.

[51] Otero T, Garcia J, Diaz-Castro S, et al. Stem cell therapy for spinal cord injury: A meta-analysis. Stem Cells Dev. 2023;32(4):153–64.

[52] Papadopoulos A, Benabid AL, Collet P, et al. Advances in stem cell therapy for neurodegenerative diseases. Neuropharmacology. 2024; 164:107859.

[53] Pati F, Jang J, Ha D, et al. 3D printing of tissues and organs. Biotechnol Adv. 2014;32(2):108–19.

[54] Pettinger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019; 4:22.

[55] Qian X, Song H, Ming GL. Brain organoids: Advances, applications, and challenges. Nat Rev Neurosci. 2022;23(9):528–44.

[56] Reiss M, Gorman H, Taylor J, et al. Personalized regenerative medicine: Stem cell-based therapies for heart disease. Stem Cell Rep. 2024;19(3):514–23.

[57] Ramos T, Zhao L, Wang X, et al. The dangers of unregulated stem cell clinics: A systematic review. JAMA. 2024;331(10):1035–43.

[58] Ryu JH, Woo JS, Son YJ, et al. The therapeutic potential of mesenchymal stem cells in treating bone defects: Current perspectives and future directions. Front Med. 2023;10(4):330–43.

[59] Salazar-Gonzalez J, Luna-Camacho M, Martinez-Perez L, et al. Stem cell-based immunomodulation in autoimmune disease therapy. Stem Cells Transl Med. 2023;12(6):751-60.

[60] Schneider M, Marquez C, Zong S, et al. Stem cell-based therapies in diabetic wound healing: Current status and future potential. J Diabetes Res. 2024; 2024:1293457.

[61] Sharma A, Neelakantan A, Cheng S, et al. Organ regeneration using stem cell-based scaffolds. Biomaterials Sci. 2023;11(3):455–69.

[62] Smith T, Zeng X, Zhang Y, et al. Bioprinting and stem cell therapies: Advancing tissue regeneration through interdisciplinary collaborations. Biomaterials. 2023;47(9):206–18.

[63] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.

[64] Tan W, Zhang Z, Wu X, et al. Telomere extension and its implications for aging and regenerative therapies. Cell Stem Cell. 2024;24(7):1007–16.

[65] Tang P, Wang D, Xie X, et al. Role of stem cell therapy in cardiovascular disease: Advances and challenges. Front Cardiovasc Med. 2023; 10:23–32.

[66] Taylor D, Clark D, Kettering S, et al. Legal frameworks and regulatory policies on the use of human embryos in stem cell research. Cell Stem Cell. 2023;16(3):287–92.

[67] Thomas H, Banks D, Clements T, et al. Developing artificial organs from stem cells: Applications and challenges. Nat Mater. 2023;22(6):573–85.

[68] Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17(3):194–200.

[69] Tufféry A, Chapey A, Kerdraon O, et al. Advances in stem cell therapy for spinal cord injury: clinical perspectives. Front Neurol. 2023; 14:682611.

[70] U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy (RMAT) Designation. FDA Guidance, 2023. Available at: www.fda.gov.

[71] Wang C, Lee J, Kim H, et al. Kidney regeneration using renal progenitor cells in chronic kidney disease. Stem Cell Rev Rep. 2023;19(3):271–82.

[72] Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Yen BL. Human mesenchymal stem cells (MSCs) for treatment towards immune and inflammatory diseases: review of current clinical trials. J Biomed Sci. 2021;28(1):64.

[73] Wang T, Xu L, Zhang Y, et al. Real-time monitoring of stem cell cultures with AI technologies: Applications in clinical trials. Stem Cells Transl Med. 2024;13(4):895–903.

[74] World Health Organization. Equitable Access to Regenerative Medicine: A Global Framework. WHO Report. 2024;11(3):68–75. Wang C, Lee J, Kim H, et al. Kidney regeneration using renal progenitor cells in chronic kidney disease. Stem Cell Rev Rep. 2023;19(3):271–82.

[75] Wong D, Takahashi K, Lu X, et al. CRISPR-Cas9 and personalized stem cell therapies: Precision medicine for genetic disorders. J Clin Investig. 2024;134(6):1128–39.

[76] Xu L, Wang J, Liu Y, et al. CRISPR-based reprogramming of T-cells into iPSCs for immunotherapy. Nat Biotechnol. 2023;41(1):40–7.

[77] Yu X, Zhao J, Zhang H, et al. Mesenchymal stem cell-based strategies for bone tissue engineering in orthopedics. Stem Cell Rev Rep. 2023;19(1):88–99.

[78] Yu Z, Wang J, Zhang Y, et al. CRISPR-Cas9-mediated genome editing in stem cell therapy: Enhancing safety and efficacy. Stem Cell Rep. 2024;13(4):1017–28.

[79] Zhang L, Gao L, Liu X, et al. Standardization of stem cell differentiation and characterization: Moving toward reproducibility in clinical trials. Cell Stem Cell. 2024;29(1):35–47.

[80] Yang L, Guell M, Byrne S, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science. 2021;350(6264):1101–4.

[81] Zhang M, Chen X, Zhao X, et al. PEGylation of scaffold materials improves biocompatibility and reduces immune response. Biomater Sci. 2024;12(3):737–48.

[82] Zhang P, Yang Y, Chen Z, et al. Advances in stem cell-based therapies for heart regeneration. J Heart Lung Transplant. 2024;43(1):47–58.

[83] Zhang S, Liu X, Liang Y, et al. Silk fibroin-based scaffolds for neural tissue engineering: Advances and challenges. Mater Sci Eng C. 2023; 147:111227.

[84] Zhang Y, Li W, Laurent T. A chemical approach to reprogramming: Small molecules as modulators of stem cell fate. Chem Soc Rev. 2023;52(3):1458–77.

[85] Zhang Y, Zhang L, Zhang Z, et al. Collagen-PLGA composite scaffold for osteochondral defect repair. Biomaterials. 2024; 270:120722.

[86] Zhang Y, Wang J, Liu H, et al. iPSC-derived β-cell replacement in type 1 diabetes. Nat Commun. 2024;15(1):97–105.

[87] Zhang Y, Liu D, Wang S, et al. Artificial intelligence in stem cell research: A new frontier for diagnostics and personalized therapies. J Clin Med. 2024;13(2):198–210.

[88] Zheng Y, Fu X, Xue Y, et al. Use of cardiac progenitor cells in myocardial infarction repair. Stem Cells Transl Med. 2023;12(11):1515-24.

[89] Zhou Z, Yang F, Chen X, et al. Artificial intelligence in stem cell research: Revolutionizing diagnostics and personalized treatments. J Stem Cell Res Ther. 2024;15(3):152–63.